This is therefore a comparing of the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership in Sutro Biopharma Inc. (NASDAQ:STRO) and CRISPR Therapeutics AG (NASDAQ:CRSP). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma Inc. 11 0.19 9.29M -1.66 0.00
CRISPR Therapeutics AG 55 0.00 34.37M -3.74 0.00

Demonstrates Sutro Biopharma Inc. and CRISPR Therapeutics AG earnings per share, gross revenue and valuation.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Sutro Biopharma Inc. 88,056,872.04% 0% 0%
CRISPR Therapeutics AG 62,388,818.30% -50.9% -39.8%

Liquidity

5.7 and 5.7 are the respective Current Ratio and a Quick Ratio of Sutro Biopharma Inc. Its rival CRISPR Therapeutics AG’s Current and Quick Ratios are 15.8 and 15.8 respectively. CRISPR Therapeutics AG has a better chance of clearing its pay short and long-term debts than Sutro Biopharma Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Sutro Biopharma Inc. and CRISPR Therapeutics AG.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sutro Biopharma Inc. 0 0 1 3.00
CRISPR Therapeutics AG 0 0 4 3.00

Sutro Biopharma Inc.’s upside potential is 58.26% at a $16 average target price. On the other hand, CRISPR Therapeutics AG’s potential downside is -8.11% and its average target price is $66.5. The information presented earlier suggests that Sutro Biopharma Inc. looks more robust than CRISPR Therapeutics AG as far as analyst view.

Institutional & Insider Ownership

Sutro Biopharma Inc. and CRISPR Therapeutics AG has shares held by institutional investors as follows: 73.1% and 50%. About 21.23% of Sutro Biopharma Inc.’s share are held by insiders. Comparatively, insiders own roughly 2% of CRISPR Therapeutics AG’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sutro Biopharma Inc. 1.9% -4.09% 13.27% 5.52% 0% 24.94%
CRISPR Therapeutics AG 3.15% 6.25% 30.58% 57.23% 7.51% 77.42%

For the past year Sutro Biopharma Inc. has weaker performance than CRISPR Therapeutics AG

Summary

Sutro Biopharma Inc. beats CRISPR Therapeutics AG on 7 of the 11 factors.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link